menu
    • menu
    [{"orgOrder":0,"company":"Nucleome Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery Platform","graph3":"Nucleome Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nucleome Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nucleome Therapeutics \/ M Ventures"},{"orgOrder":0,"company":"Nucleome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2026","type":"Inapplicable","leadProduct":"NTP464","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Nucleome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nucleome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Nucleome Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Nucleome Therapeutics

    Menu

    Nucleome Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nucleome Therapeutics

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Nucleome Therapeutics

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTP464

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nucleome Therapeutics Nominates First Preclinical Development Candidate

                            Details : NTP464, an unconjugated antibody, shows promising results in targeting inflammation, offering potential therapeutic benefits.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            January 07, 2026

                            Lead Product(s) : NTP464

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nucleome Therapeutics

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Nucleome Therapeutics

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Discovery Platform

                            Sponsor : M Ventures

                            Deal Size : $43.2 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Nucleome Therapeutics Raises Oversubscribed £37.5 Million Series A Financing to Decode the Dark Matter of The...

                            Details : The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 19, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery Platform

                            Sponsor : M Ventures

                            Deal Size : $43.2 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.